KR20090007226A - Nano-particles containing calcium and method for preparing the same - Google Patents
Nano-particles containing calcium and method for preparing the same Download PDFInfo
- Publication number
- KR20090007226A KR20090007226A KR1020080067357A KR20080067357A KR20090007226A KR 20090007226 A KR20090007226 A KR 20090007226A KR 1020080067357 A KR1020080067357 A KR 1020080067357A KR 20080067357 A KR20080067357 A KR 20080067357A KR 20090007226 A KR20090007226 A KR 20090007226A
- Authority
- KR
- South Korea
- Prior art keywords
- calcium
- containing nanoparticles
- producing
- solvent
- polysaccharide compound
- Prior art date
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 124
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 123
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 121
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 27
- -1 polysaccharide compound Chemical class 0.000 claims abstract description 27
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 25
- 239000005017 polysaccharide Substances 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 18
- 229960005069 calcium Drugs 0.000 claims description 117
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 229910001868 water Inorganic materials 0.000 claims description 16
- 235000013376 functional food Nutrition 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- 229960003563 calcium carbonate Drugs 0.000 claims description 9
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 229940069978 calcium supplement Drugs 0.000 claims description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229960001714 calcium phosphate Drugs 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 5
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 4
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- 229960002079 calcium pantothenate Drugs 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 3
- 239000001639 calcium acetate Substances 0.000 claims description 3
- 235000011092 calcium acetate Nutrition 0.000 claims description 3
- 229960005147 calcium acetate Drugs 0.000 claims description 3
- 239000000648 calcium alginate Substances 0.000 claims description 3
- 235000010410 calcium alginate Nutrition 0.000 claims description 3
- 229960002681 calcium alginate Drugs 0.000 claims description 3
- 239000011692 calcium ascorbate Substances 0.000 claims description 3
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 3
- 229940047036 calcium ascorbate Drugs 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 229960004256 calcium citrate Drugs 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 229940095643 calcium hydroxide Drugs 0.000 claims description 3
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000292 calcium oxide Substances 0.000 claims description 3
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 3
- 239000004330 calcium propionate Substances 0.000 claims description 3
- 235000010331 calcium propionate Nutrition 0.000 claims description 3
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 claims description 3
- 235000010244 calcium sorbate Nutrition 0.000 claims description 3
- 239000004303 calcium sorbate Substances 0.000 claims description 3
- 235000011132 calcium sulphate Nutrition 0.000 claims description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 3
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000001223 reverse osmosis Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 1
- 229940087373 calcium oxide Drugs 0.000 claims 1
- 235000012255 calcium oxide Nutrition 0.000 claims 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 claims 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 1
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 3
- 238000007670 refining Methods 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241001454694 Clupeiformes Species 0.000 description 3
- 206010020100 Hip fracture Diseases 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 235000019513 anchovy Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
- 208000007442 rickets Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 229940043430 calcium compound Drugs 0.000 description 2
- 150000001674 calcium compounds Chemical class 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OMRDZQXXMYCHBU-UHFFFAOYSA-N ethanol;propan-1-ol Chemical compound CCO.CCCO OMRDZQXXMYCHBU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 208000005368 osteomalacia Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011257 shell material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/25—Nanoparticles, nanostructures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1578—Calcium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Geology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Abstract
Description
본 발명은 칼슘을 함유하는 나노입자 및 그 제조방법에 관한 것으로서, 더욱 상세하게는 기존의 칼슘제보다 흡수율이 탁월하고, 고순도와 일정한 형태의 나노 구조를 가지며, 제조공정이 간단하고 고가의 장비를 사용하지 않음에 따라 대량 생산이 용이한, 칼슘을 함유하는 나노입자 및 그 제조방법에 관한 것이다.The present invention relates to nanoparticles containing calcium and a method of manufacturing the same, and more particularly, the absorption rate is superior to the conventional calcium agent, has a high purity and a certain type of nanostructure, the manufacturing process is simple and uses expensive equipment The present invention relates to a nanoparticle containing calcium and a method for producing the same, which are not easily mass-produced.
칼슘은 인체 내에서 가장 풍부한 무기질 중의 하나이며 꼭 필요한 요소이다. 총 몸무게의 약 2%는 칼슘으로 되어 있는데, 인체 칼슘 량의 99%는 뼈에 들어 있다. 칼슘은 뼈와 치아를 구성하고 유지시키는 중요한 역할뿐만 아니라 인체 효소 활동의 많은 부분에서도 중요한 역할을 한다. 또한 근육의 수축과 신경 전달 물질의 방출, 심장 박동의 조절, 혈액 응고 작용에 관여한다. Calcium is one of the most abundant minerals in the body and is a must. About 2% of the total weight is made of calcium, and 99% of the body's calcium is in the bones. Calcium plays an important role in many parts of human enzyme activity as well as in the formation and maintenance of bones and teeth. It is also involved in the contraction of muscles and the release of neurotransmitters, regulation of the heart rate, blood clotting.
칼슘이 인체에 부족하게 되면 어린이들의 경우, 구루병을 유발시킬 수 있다. 상기 구루병은 뼈의 기형과 성장 발달의 저하를 초래할 수 있기 때문에 청소년기에 일정량의 칼슘 섭취는 매우 중요하다. 또한 성인들의 경우, 칼슘 결핍은 골연화증을 유발할 수 있고 낮은 혈중 칼슘 수치는 근육 경직과 다리의 경련을 유발할 수 있으며, 또한 고혈압과 골다공증, 결장암의 원인이 될 수도 있다. Lack of calcium in the body can cause rickets in children. Since the rickets disease may cause bone deformity and deterioration of growth development, a certain amount of calcium intake in adolescence is very important. In adults, calcium deficiency can lead to osteomalacia, low blood calcium levels can lead to muscle stiffness and leg cramps, and can also cause high blood pressure, osteoporosis and colon cancer.
특히 골다골증은 문자대로 '뼈에 구멍이 생기는 것'을 의미하며, 미국에서는 2000 만명 이상의 사람들이 골다공증에 걸려 있다. Osteoporosis, in particular, literally means `` a hole in the bone, '' and in the United States more than 20 million people have osteoporosis.
골다공증은 일반적으로 남성과 여성 모두 40세가 넘으면 뼈의 질량 감소를 경험하게 되나, 골다공증에 걸릴 위험성은 여성들이 훨씬 더 많다. 상기 골다공증는 과도한 뼈의 소실은 많은 요인들로 인해 일어나며, 그 형태도 다양하며, 그 중 여성의 폐경기 이후의 골다공증이 가장 흔한 형태이다. 알려진 바로는, 폐경기 이후 여성의 약 1/4이 골다공증에 걸리게 되며, 대개 척추와 엉덩이, 갈비뼈의 소실이 가장 크나, 심한 경우 골격 전체가 폐경기 이후의 골다공증에 영향을 받을 수 있다. Osteoporosis is generally experienced by both men and women over 40 years of bone mass loss, but women are at greater risk of developing osteoporosis. The osteoporosis is caused by a number of factors due to excessive bone loss, the form is also varied, the post-menopausal osteoporosis of women is the most common form. It is known that about one-fourth of women develop postmenopausal osteoporosis, and the loss of the spine, hips, and ribs is usually the largest, but in severe cases the entire skeleton can be affected by postmenopausal osteoporosis.
인체 내의 뼈들은 큰 무게를 지탱하기 때문에, 통증과 기형 또는 골절 파손에 민감하다. 골다공증의 직접적인 결과로, 매년 최소한 1천 5백만 건의 골절 파손이 발생하며, 이들 중 약 2%는 엉덩이뼈 파손인데, 이는 대부분의 환자들에게 아주 끔찍한 파손이다. 엉덩이 골절 파손의 12~20%는 아주 치명적인 것으로, 생존자들의 반은 장기 입원 치료를 받아야 하며, 여성들의 1/3과 남성들의 1/6이 엉덩이 골절 파손을 경험하게 될 것이다.Since the bones in the human body carry large weights, they are sensitive to pain and malformations or fracture breakage. As a direct result of osteoporosis, at least 15 million fractures occur each year, about 2% of which are hip fractures, a very terrible injury for most patients. 12-20% of hip fractures are very fatal, with half of survivors undergoing long-term inpatient treatment, with one third of women and one-sixth of men experiencing hip fractures.
종래에는 골다공증 치료를 위해 주로 이온화 칼슘액, 굴 껍질을 이용하여 제조된 칼슘, 동물의 뼈, 우유, 멸치 등을 복용해 왔다. 그러나 골 밀도를 높이기 위해 이온화 칼슘을 복용할 시, 체내 중금속까지 함께 뼈에 흡착시키는 문제, 동물의 뼈는 체내결석을 발생시키는 문제를 야기할 수 있다. 또한 멸치는 현재 먹는 방법 으로는 흡수력이 매우 저조하여 멸치가 함유하고 있는 칼슘 성분의 오직 1% 정도만 체내에 흡수될 뿐이므로 종래의 이러한 칼슘 보급은 근본적으로 골다공증 전개의 지연 효과만 있을 뿐 완치를 구현할 수 없었다. Conventionally, for the treatment of osteoporosis, ionized calcium liquid, calcium prepared using oyster shells, animal bones, milk, anchovies, and the like have been taken. However, when taking ionized calcium to increase bone density, the problem of adsorption of heavy metals in the body together with bones, and bones of animals can cause problems in the body. In addition, anchovies are currently very poorly absorbed, and only 1% of the anchovy's calcium content is absorbed into the body. Therefore, the conventional calcium supplementation has only a delay in the development of osteoporosis, which can be cured. Could not.
이러한 문제를 해결하기 위해 많은 연구팀과 기업들이 고순도, 고흡수율과 이온화되기 쉬운 칼슘 보충제 개발에 박차를 가하고 있다.To solve this problem, many research teams and companies are spurring the development of calcium supplements with high purity, high absorption rate and easy ionization.
현재 대부분 복용 및 판매되고 있는 칼슘 보충제는 주성분이 탄산칼슘이다. 상기 탄산칼슘이 주성분인 칼슘 보충제를 일반인이 복용하였을 경우 위액과 작용하여 이온화되는 정도가 20% 정도이고, 위액 분비가 적은 환자가 복용하였을 경우 4%정도 인 것으로 밝혀졌다. 이와 같은 현상이 일어나는 원인은 탄산칼슘이 쉽게 이온화되기 위해서는 녹기 쉬운 상태가 된 다음 위액과 반응해야 이온화도가 커지는데, 탄산칼슘은 녹는점(825℃)이 높고,상온에서 물에 잘 녹지 않기 때문에 이온화하기 쉽지 않다. Calcium supplements that are currently taken and sold most are calcium carbonate. When the general public took the calcium supplement, which is the main ingredient of calcium carbonate, it was found that the degree of ionization by interacting with gastric juice was about 20%, and about 4% when the patient had little secretion of gastric juice. The cause of this phenomenon is that calcium carbonate must be easily dissolved and then reacted with gastric fluid to increase its ionization.The calcium carbonate has a high melting point (825 ℃) and is not soluble in water at room temperature. Not easy to do
그러나 그 크기를 나노 단위로 제조하게 되면 나노 물질의 특성상 표면적이 극대화되어 이온화도가 증가하기 때문에 인체 내의 흡수율을 높일 수 있는 효과를 얻을 수 있다. 이에 나노 수준의 입자 크기를 가지는 나노 칼슘을 제조하고자 하는 연구가 진행되고 있다. However, if the size is manufactured in nano units, the surface area is maximized due to the characteristics of the nanomaterial, and thus the ionization degree is increased, thereby increasing the absorption rate in the human body. In order to produce nano-calcium having a particle size of the nano-level has been researched.
나노 과학 기술 분야에서 잘 알려진 대로 물질을 구성하고 있는 원자의 보어 반경보다 입자가 작아질 경우 급격한 물리-화학적 특성변화에 의해 예상치 못한 특성이 발견될 수 있다. 이론적으로 칼슘의 보어 반지름이 0.19 nm이기 때문에 수십-수백 나노미터 사이즈의 크기를 갖는 나노 칼슘의 경우에는 예상치 못한 독성의 발생 등의 문제점이 없으며 일반 벌크 사이즈의 칼슘에 비해 흡수율이 크게 증가하는 이점이 있다.As is well known in the field of nanotechnology, unexpected properties can be found by rapid physico-chemical characterization when particles become smaller than the bore radius of the atoms that make up the material. Theoretically, since the bore radius of calcium is 0.19 nm, nano-calciums having sizes of tens to hundreds of nanometers do not have problems such as unexpected toxicity and have a significant increase in absorption compared to regular bulk calcium. have.
대한민국 특허 공개 제2006-91675호(체내 칼슘 흡수율을 높인 굴 껍질 나노분말의 제조 방법)는 전복이나 굴 껍질을 파쇄하여 나노 수준의 입자 크기를 갖는 나노 칼슘의 제조방법을 언급하고 있다. 상기 특허에 기재된 파쇄법으로 얻어진 나노 칼슘의 분석표를 살펴보면, 칼슘 성분 이외의 Fe2O3, Al2O3, MgO, SiO2, Pb, As, Ba, Mg, 알칼리염(Alkaline salt)과 같은 불순물들이 포함되어 있다. 이는 상기 방법으로 얻어진 나노 칼슘을 장기간 복용 시 독극물인 As(비소) 및 중금속인 Pb(납) 성분이 상당량 체내에 축적되어 인체에 치명적인 결과를 초래할 수 있음을 의미한다.Korean Patent Laid-Open Publication No. 2006-91675 (Method for preparing oyster shell nanopowder having increased calcium absorption in the body) refers to a method for preparing nanocalcium having nano-level particle size by crushing abalone or oyster shell. Looking at the analysis table of nano calcium obtained by the crushing method described in the patent, Fe 2 O 3 , Al 2 O 3 , MgO, SiO 2 , Pb, As, Ba, Mg, alkaline salts other than the calcium component Impurities are included. This means that long-term use of the nano calcium obtained by the above method can accumulate a significant amount of poisonous As (arsenic) and heavy metal Pb (lead) in the body, which may cause fatal effects on the human body.
더욱이 상기 특허에서 제시하는 나노 칼슘은 나노사이즈의 구형으로 존재하는 나노 입자 형태를 갖는다. 이러한 나노 입자들은 표면에너지를 낮추기 위해 서로 응집되기 쉬어 나노화에 따른 흡수율의 탁월한 향상을 기대하기 어렵다.Furthermore, the nano calcium presented in the patent has a nano particle form present in a nano size sphere. These nanoparticles tend to aggregate with each other in order to lower surface energy, and thus, it is difficult to expect an excellent improvement in absorption rate due to nanoization.
상기한 종래 기술의 문제점들을 해결하고자, 본 발명은 칼슘 함유 입자의 크기를 예컨대 1㎛, 보다 바람직하게는 1 nm 내지 900 nm 범위의 나노미터 수준으로 제어하고 응집이 발생하지 않으며, 대량 생산에 용이하게 적용할 수 있도록 공정이 단순화된 칼슘함유 나노입자 및 그 제조방법을 제공하는 것을 기술적 과제로 한다.In order to solve the above-mentioned problems of the prior art, the present invention controls the size of the calcium-containing particles to a nanometer level, for example, in the range of 1 μm, more preferably 1 nm to 900 nm, no aggregation occurs, and is easy for mass production. It is a technical object of the present invention to provide a calcium-containing nanoparticle and a method for manufacturing the same, which are simplified in the process.
본 발명에 따르면, 칼슘 공급원 물질과 용매가 혼합된 용액에 다당류 화합물을 첨가하는 것을 특징으로 하는 칼슘 함유 나노 입자의 제조방법이 제공된다.According to the present invention, there is provided a method for producing calcium-containing nanoparticles, wherein the polysaccharide compound is added to a solution in which a calcium source material and a solvent are mixed.
본 발명의 일 구체예에 따르면, 본 발명의 칼슘 함유 나노 입자는According to one embodiment of the present invention, the calcium-containing nanoparticles of the present invention
(1) 칼슘 공급원 물질을 용매에 용해시키는 단계,(1) dissolving the calcium source material in a solvent,
(2) 상기 (1)단계에서 얻어진 용액에 다당류 화합물을 첨가하고 교반하는 단계, 및(2) adding and stirring a polysaccharide compound to the solution obtained in step (1), and
(3) 상기 (2)단계에서 얻어진 용액으로부터 칼슘 함유 나노 입자를 분리 및 정제하는 단계를 거쳐 제조된다.(3) is prepared through the step of separating and purifying the calcium-containing nanoparticles from the solution obtained in step (2).
본 발명에 있어서 상기 칼슘 공급원 물질에는 특별한 제한이 없으며, 바람직하게는 기능성 식품 또는 의료용 원료물질로서 적당한 칼슘 화합물을 사용한다. 구체적으로는 구연산칼슘, 글루콘산칼슘, 수산화칼슘, 염화칼슘, 질산칼슘, 젖산칼슘, 제삼인산칼슘, 제이인산칼슘, 제일인산칼슘, 탄산칼슘, 판토텐산칼슘, 프로피온산칼슘, 황산칼슘, 글리세로인산칼슘, 산화칼슘, 아스코르빈산칼슘, 알긴산칼슘, 초산칼슘, 소르빈산칼슘, 패각 유래 칼슘물질, 해조칼슘 및 이들의 조합으로 이루어진 군에서 선택된 것이 칼슘 공급원 물질로서 사용가능하다.In the present invention, the calcium source material is not particularly limited, and preferably a suitable calcium compound is used as the functional food or medical raw material. Specifically, calcium citrate, calcium gluconate, calcium hydroxide, calcium chloride, calcium nitrate, calcium lactate, tricalcium phosphate, dibasic calcium phosphate, calcium phosphate, calcium carbonate, calcium pantothenate, calcium propionate, calcium sulfate, calcium phosphate, and oxide Any one selected from the group consisting of calcium, calcium ascorbate, calcium alginate, calcium acetate, calcium sorbate, shell-derived calcium material, seaweed calcium and combinations thereof can be used as the calcium source material.
본 발명에 있어서 상기 용매로는 상기한 바와 같은 칼슘 공급원 물질을 상온에서 또는 가열하여 용해시킬 수 있는 것이라면 제한없이 사용가능하며, 바람직하게는 기능성 식품 또는 의료용 원료물질의 제조에 적합한 용매를 사용한다. 구체적으로는 물, 저급 알코올(예컨대, 메탄올, 에탄올 프로판올 등과 같은 탄소수 1 내 지 6의 알코올), 아세톤, 아세트산 수용액, 및 이들의 조합으로 이루어진 군에서 선택된 것이 용매로서 사용가능하다.In the present invention, the solvent may be used without limitation as long as it can dissolve the calcium source material as described above at room temperature or by heating, and preferably a solvent suitable for the production of functional food or medical raw materials is used. Specifically, a solvent selected from the group consisting of water, lower alcohols (eg, alcohols having 1 to 6 carbon atoms such as methanol, ethanol propanol, etc.), acetone, acetic acid aqueous solution, and combinations thereof can be used.
본 발명에 있어서 상기 다당류 화합물의 종류에는 특별한 제한이 없으며, 천연 또는 합성 다당류 화합물이 모두 사용가능하다. 바람직하게는, 전분, 키틴, 키토산, 알긴산, 카르복시메틸셀룰로오스(CMC), 히드록시메틸셀룰로오스(HMC), 히드록시에틸셀룰로오스(HEC), 히드록시프로필셀룰로오스(HPC), 히드록시프로필메틸셀룰로오스(HPMC) 및 이들의 조합으로 이루어진 군에서 선택된 것이 사용된다.In the present invention, the type of the polysaccharide compound is not particularly limited, and both natural and synthetic polysaccharide compounds may be used. Preferably, starch, chitin, chitosan, alginic acid, carboxymethyl cellulose (CMC), hydroxymethyl cellulose (HMC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC ) And combinations thereof are used.
본 발명에 따라 제조된 칼슘 함유 나노 입자는 바람직하게는 1 ㎛ 이하, 보다 바람직하게는 1 nm 내지 900 nm의 직경을 갖는다.The calcium-containing nanoparticles prepared according to the present invention preferably have a diameter of 1 μm or less, more preferably 1 nm to 900 nm.
본 발명을 통해 인체에 무해한 원료를 사용한 화학 합성방법으로 칼슘 함유 나노 입자의 대량 생산이 가능하다. 상기 제조된 칼슘 함유 나노 입자는 나노 수준으로 조절된 입자 크기를 갖고, 고흡수율과 고순도를 가지며, 생체 투여시 위장에서의 흡수/소화 과정을 거치지 않도록 조절될 수 있다. 본 발명의 칼슘 함유 나노 입자 제조방법에서는 종래의 나노칼슘제 제조기술과 달리 고가의 장비를 사용하지 않고, 간단한 공정으로 대량생산이 가능하기 때문에, 저렴한 가격으로 나노 칼슘제의 유통을 가능케 한다. Through the present invention, it is possible to mass-produce calcium-containing nanoparticles by chemical synthesis using harmless raw materials. The prepared calcium-containing nanoparticles have a particle size adjusted to the nano level, have a high absorption rate and high purity, and can be adjusted so as not to undergo the absorption / digestion process in the gastrointestinal tract during the administration of the biomass. In the method of producing calcium-containing nanoparticles of the present invention, unlike conventional nanocalcium production techniques, expensive production is possible without using expensive equipment, and thus mass distribution is possible at a low price.
이하 본 발명의 칼슘함유 나노입자 제조방법을 단계별로 상세히 설명한다.Hereinafter, the method for preparing calcium-containing nanoparticles of the present invention will be described in detail step by step.
(1) 단계: 칼슘 공급원 물질의 용해 단계(1) step: dissolution of calcium source material
칼슘 공급원 물질을 용매에 투입한 후 필요에 따라 가열 및 교반하여 용해시킨다.The calcium source material is added to a solvent and then dissolved by heating and stirring as necessary.
칼슘 공급원 물질의 종류에는 특별한 제한이 없으며, 바람직하게는 기능성 식품 또는 의료용 원료물질로서 적당한 칼슘 화합물을 사용한다. 식품 의약품 안전청에서 안전성이 인정된 원료를 사용하는 것이 바람직하다. 구체적으로는 구연산칼슘, 글루콘산칼슘, 수산화칼슘, 염화칼슘, 질산칼슘, 젖산칼슘, 제삼인산칼슘, 제이인산칼슘, 제일인산칼슘, 탄산칼슘, 판토텐산칼슘, 프로피온산칼슘, 황산칼슘, 글리세로인산칼슘, 산화칼슘, 아스코르빈산칼슘, 알긴산칼슘, 초산칼슘, 소르빈산칼슘, 패각 유래 칼슘물질, 해조칼슘 및 이들의 조합으로 이루어진 군에서 선택된 것이 칼슘 공급원 물질로서 사용가능하다.There is no particular limitation on the kind of calcium source material, and preferably, suitable calcium compounds are used as functional food or medical raw materials. It is advisable to use ingredients that have been recognized as safe by the Food and Drug Administration. Specifically, calcium citrate, calcium gluconate, calcium hydroxide, calcium chloride, calcium nitrate, calcium lactate, tricalcium phosphate, dibasic calcium phosphate, calcium phosphate, calcium carbonate, calcium pantothenate, calcium propionate, calcium sulfate, calcium phosphate, and oxide Any one selected from the group consisting of calcium, calcium ascorbate, calcium alginate, calcium acetate, calcium sorbate, shell-derived calcium material, seaweed calcium and combinations thereof can be used as the calcium source material.
용매로는 칼슘 공급원 물질을 용해시킬 수 있는 것이라면 제한없이 사용가능하며, 바람직하게는 기능성 식품 또는 의료용 원료물질의 제조에 적합한 용매를 사용한다. 구체적으로는 물, 저급 알코올(예컨대, 메탄올, 에탄올 프로판올 등과 같은 탄소수 1 내지 6의 알코올), 아세톤, 아세트산 수용액, 및 이들의 조합으로 이루어진 군에서 선택된 것이 용매로서 사용가능하다. 인체에 무해한 물을 사용하는 것이 바람직하다.As the solvent, any solvent capable of dissolving the calcium source material can be used without limitation, and preferably a solvent suitable for the production of the functional food or medical raw material is used. Specifically, one selected from the group consisting of water, lower alcohols (for example, alcohols having 1 to 6 carbon atoms such as methanol, ethanol propanol, etc.), acetone, acetic acid aqueous solution, and combinations thereof can be used as the solvent. It is preferable to use water which is harmless to the human body.
칼슘 공급원 물질의 사용량은 선택된 용매 내의 용해도를 고려하여 적절히 선택될 수 있다. 예컨대 물을 용매로서 사용하는 경우 0.001 M 내지 0.5 M 농도 범위 내에서 칼슘 공급원의 용액 농도가 결정되도록 하는 것이 바람직하나, 이에 반 드시 제한되는 것은 아니다. 다만, 칼슘 공급원 물질의 사용량이 지나치게 적으면 제조공정의 생산성 및 효율성이 낮아질 수 있고, 지나치게 많으면 나노 입자가 효과적으로 형성되지 못할 수도 있다.The amount of calcium source material used may be appropriately selected in view of the solubility in the selected solvent. For example, when water is used as the solvent, it is preferable to allow the solution concentration of the calcium source to be determined within the concentration range of 0.001 M to 0.5 M, but is not limited thereto. However, if the amount of the calcium source material is used too little, the productivity and efficiency of the manufacturing process may be lowered. If the amount is too high, nanoparticles may not be effectively formed.
칼슘 공급원 물질의 용해시 온도조건에는 특별한 제한이 없다. 따라서 상온에서도 칼슘 공급원 물질을 용매에 용해시킬 수 있으나, 보다 완전하고 신속한 용해를 얻기 위하여 가열을 하는 것이 바람직하다. 가열 온도조건에는 특별한 제한이 없으며, 예컨대 25 내지 150 ℃, 바람직하게는 90 내지 110 ℃ 범위 내에서 용매의 끓는점을 고려하여 적절히 선택할 수 있다. 칼슘 공급원 물질의 용해는 0.5 내지 24 시간 동안 수행할 수 있으나, 이에 제한되는 것은 아니다. There is no particular restriction on the temperature conditions upon dissolution of the calcium source material. Thus, the calcium source material may be dissolved in the solvent even at room temperature, but heating is preferred to obtain more complete and rapid dissolution. There is no particular limitation on the heating temperature conditions, and for example, the boiling point of the solvent may be appropriately selected within the range of 25 to 150 ° C, preferably 90 to 110 ° C. Dissolution of the calcium source material may be performed for 0.5 to 24 hours, but is not limited thereto.
칼슘 공급원 물질의 용해시 원료의 종류에 따라 용매 내에서 다양한 반응이 일어난다. 일 예로 탄산칼슘의 경우 하기 반응식 1과 같은 반응이 일어난다.When dissolving the calcium source material, various reactions occur in the solvent depending on the type of raw material. For example, in the case of calcium carbonate, a reaction as in
상기 반응식 1에 나타난 바와 같이, 탄산칼슘을 원료로 사용하는 경우 물에 용해시키면, 칼슘 이온으로 이온화하고 이산화탄소 및 물이 발생한다. 이때 발생한 이산화탄소는 기체가 되어 반응기로부터 배출된다.As shown in
(2) 단계: 다당류 화합물의 첨가 단계(2) step: addition of the polysaccharide compound
상기 (1)단계에서 얻어진 칼슘 공급원 물질의 용액 내에 다당류 화합물을 첨 가하고 교반하여 칼슘 함유 나노 입자를 형성한다. 이온화된 칼슘을 포함하는 용액에 다당류 화합물을 첨가하면, 다당류 화합물이 칼슘 이온들과 이온성 결합을 형성하면서 일종의 복합체 구조물을 형성하는 것으로 판단된다. The polysaccharide compound is added to the solution of the calcium source material obtained in step (1) and stirred to form calcium-containing nanoparticles. When a polysaccharide compound is added to a solution containing ionized calcium, it is determined that the polysaccharide compound forms a kind of complex structure while forming an ionic bond with calcium ions.
다당류 화합물의 사용량에는 특별한 제한이 없으며, 용매 대비 다당류 화합물의 용해도를 고려하여 용매 100중량부당 50중량부 이내의 범위 내에서 사용한다. 또한, 용액 중의 칼슘 공급원 물질 1몰당 0.01 내지 10몰의 범위 내에서 적절히 선택하는 것이 바람직하다. 만약 다당류 화합물의 농도가 상기한 수준보다 낮으면 칼슘 함유 입자의 크기가 커질 우려가 있고, 상기 범위를 초과하면 과도한 다당류 화합물의 사용으로 칼슘 함유 나노 입자의 순도 및 함량의 저하를 초래할 수 있다.There is no particular restriction on the amount of the polysaccharide compound, and considering the solubility of the polysaccharide compound relative to the solvent, the polysaccharide compound is used within a range of 50 parts by weight per 100 parts by weight of the solvent. It is also desirable to select appropriately within the range of 0.01 to 10 moles per mole of calcium source material in solution. If the concentration of the polysaccharide compound is lower than the above-mentioned level, the size of the calcium-containing particles may be increased, and if it exceeds the above range, the use of excessive polysaccharide compounds may lead to a decrease in the purity and content of the calcium-containing nanoparticles.
다당류 화합물로는 천연 또는 합성 다당류 화합물이 모두 사용가능하며, 인체에 무해 및 무독한 것이 바람직하다. 구체적으로는, 전분, 키틴, 키토산, 알긴산, 카르복시메틸셀룰로오스(CMC), 히드록시메틸셀룰로오스(HMC), 히드록시에틸셀룰로오스(HEC), 히드록시프로필셀룰로오스(HPC), 히드록시프로필메틸셀룰로오스(HPMC) 및 이들의 조합으로 이루어진 군에서 선택된 것이 사용된다.As the polysaccharide compound, both natural or synthetic polysaccharide compounds can be used, and those that are harmless to humans and non-toxic are preferable. Specifically, starch, chitin, chitosan, alginic acid, carboxymethyl cellulose (CMC), hydroxymethyl cellulose (HMC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC ) And combinations thereof are used.
다당류 화합물의 첨가 및 교반시 온도조건에는 특별한 제한이 없으며, 예컨대 25 내지 150 ℃, 바람직하게는 90 내지 110 ℃ 범위 내에서 용매의 끓는점 및 다당류 화합물의 종류 등을 고려하여 적절히 선택할 수 있다. 다당류 화합물의 첨가 및 교반은 0.5 내지 24 시간 동안 수행할 수 있으나, 이에 제한되지는 않는다. There are no particular limitations on the temperature conditions upon addition and stirring of the polysaccharide compound, and for example, the boiling point of the solvent and the kind of the polysaccharide compound may be appropriately selected within the range of 25 to 150 ° C, preferably 90 to 110 ° C. Addition and stirring of the polysaccharide compound may be performed for 0.5 to 24 hours, but is not limited thereto.
(3) 단계: 칼슘 함유 나노 입자의 분리 및 정제 단계(3) step: separation and purification of calcium-containing nanoparticles
상기 (2)단계에서 얻어진 용액으로부터 칼슘 함유 나노 입자만을 선택적으로 회수하기 위해 분리 공정을 수행하고, 순도를 높이기 위해 정제 공정을 수행한다.A separation process is performed to selectively recover only calcium-containing nanoparticles from the solution obtained in step (2), and a purification process is performed to increase purity.
분리 및 정제의 방법에는 특별한 제한이 없으며, 이 분야에서 공지된 분리 및 정제방법 및 장치를 그대로 또는 적절히 변형하여 수행한다. 예컨대 분리 및 정제는 필터 여과법, 흡착법, 전기 영동법, 역삼투압법, 침전법 등에 의해 수행될 수 있으며, 마이크로 필터를 이용한 분리방법이 대량 생산의 측면에서 바람직하다.There is no particular limitation on the method of separation and purification, and the separation and purification methods and apparatus known in the art are carried out as it is or as appropriately modified. For example, separation and purification can be carried out by filter filtration, adsorption, electrophoresis, reverse osmosis, precipitation, and the like. A separation method using a micro filter is preferable in terms of mass production.
본 발명의 칼슘 함유 나노 입자 제조방법에서는 상기 설명한 바와 같은 성분들 및/또는 단계들 이외에, 본 발명의 목적을 달성할 수 있는 범위 내에서 사용가능한 추가의 성분 및/또는 단계를 더 포함할 수 있다. In the method for preparing calcium-containing nanoparticles of the present invention, in addition to the components and / or steps as described above, the method may further include additional ingredients and / or steps usable within the scope of achieving the object of the present invention. .
본 발명에 따라 얻어진 칼슘 함유 나노 입자는 입자 직경이 1 ㎛ 이하, 바람직하게는 1 nm 내지 900 nm 범위의 나노미터 사이즈 크기를 갖는다.The calcium-containing nanoparticles obtained according to the present invention have a nanometer size size of less than 1 μm, preferably in the range of 1 nm to 900 nm nm.
기존의 파쇄법 등에 의해 제조된 미세 칼슘 입자가 응집되기 쉬운 단점을 갖고 있는 것과 반대로, 본 발명의 칼슘 함유 나노 입자는 입자끼리의 응집이 크게 발생하지 않으므로 용액 및 체내에서 쉽게 이온화되고 흡수되는 장점을 갖는다. 따라서 칼슘 부족에 따른 각종 질병, 예컨대 골다공증, 구루병, 골연화증, 고혈압 및 결장암과 같은 질병의 치료 및 예방에 유용하게 사용될 수 있을 뿐만 아니라 각종 고형 제제 또는 액상 음료와 같은 건강 보조 식품 형태로도 사용될 수 있다. 또한, 본 발명의 칼슘 함유 나노 입자는 혈액으로 바로 이송되어 골 밀도를 높여주며, 여 분의 칼슘 함유 입자는 혈액에 의해 체외로 배설되므로, 기존의 칼슘 보충제보다 많은 양을 섭취해도 무방하다. On the contrary, the calcium-containing nanoparticles of the present invention have the advantage of being easily ionized and absorbed in the solution and the body since the aggregation of the particles of the present invention does not occur significantly between the fine calcium particles prepared by the conventional crushing method. Have Therefore, it is not only useful for the treatment and prevention of various diseases caused by calcium deficiency such as osteoporosis, rickets, osteomalacia, hypertension and colon cancer, but also in the form of health supplements such as various solid preparations or liquid drinks. . In addition, the calcium-containing nanoparticles of the present invention is directly transferred to the blood to increase the bone density, and the extra calcium-containing particles are excreted in vitro by the blood, it is possible to take a larger amount than conventional calcium supplements.
따라서, 본 발명의 다른 측면에 따르면, 본 발명에 따라 얻어진 칼슘함유 나노 입자를 포함하는 칼슘 보충용 기능성 식품이 제공된다. 본 발명에 따라 제공될 수 있는 칼슘 보충용 기능성 식품은 본 발명에 따라 얻어진 칼슘 함유 나노 입자를 주된 기능성 성분으로 포함하는 것을 특징으로 하며, 그 외에 기능성 식품에 통상 사용되는 부형제 등 각종 첨가제 성분을 더 포함할 수 있다. 또한 상기 칼슘 보충용 기능성 식품의 제조는 당 분야에 통상 알려진 기능성 식품 제형(예컨대 정제, 캡슐제, 현탁액제 등)으로 제조가능하며, 그 제조방법에는 특별한 제한이 없다.Therefore, according to another aspect of the present invention, there is provided a functional food for calcium supplement containing calcium-containing nanoparticles obtained according to the present invention. Functional food for calcium supplement which can be provided according to the present invention is characterized in that it comprises calcium-containing nanoparticles obtained according to the present invention as the main functional ingredient, and further includes various additive components such as excipients commonly used in functional food. can do. In addition, the preparation of the calcium supplement functional food can be prepared in a functional food formulation (such as tablets, capsules, suspensions, etc.) commonly known in the art, there is no particular limitation on the preparation method.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.
[[ 실시예Example ]]
실시예Example 1 One
판토텐산 칼슘을 물에 첨가하여 25 mM 농도로 용해한 다음, 90 ℃에서 10 분 동안 가열하였다. 여기에 키토산을 12.5 mM 농도로 첨가한 후 동일 온도에서 2 시간 동안 균일하게 혼합하였다. Calcium pantothenate was added to water to dissolve at 25 mM and then heated at 90 ° C. for 10 minutes. Chitosan was added thereto at a concentration of 12.5 mM and then mixed uniformly at the same temperature for 2 hours.
상기 얻어진 혼합물을 마이크로 필터기를 이용하여 분리하고, 건조하여 흰색의 미분말 형태의 칼슘 함유 나노 입자를 얻었으며, 그 사진을 도 1에 나타내었다. The obtained mixture was separated using a micro filter and dried to obtain calcium fine nanoparticles in the form of white fine powder, and the photograph is shown in FIG. 1.
상기 얻어진 칼슘 함유 나노 입자에 대하여 전계방사 주사전자현미경(Field Emission Scanning Electron Microscope, FE-SEM)을 이용하여 입자 형태를 촬영하였다. 도 2는 실시예 1에서 제조된 칼슘 함유 나노 입자의 FE-SEM 사진이다. 도 2를 참조하면, 본 발명에 따라 제조된 나노 입자는 응집이 거의 발생하지 않았을 뿐만 아니라 입자 직경이 1 nm에서 900 nm 정도로 매우 작은 나노미터 수준의 크기를 가짐을 알 수 있다.The obtained calcium-containing nanoparticles were photographed in the form of particles using a field emission scanning electron microscope (FE-SEM). 2 is an FE-SEM photograph of the calcium-containing nanoparticles prepared in Example 1. Referring to FIG. 2, it can be seen that the nanoparticles prepared according to the present invention not only generate little agglomeration but also have a nanometer diameter of a small diameter of 1 nm to 900 nm.
또한 상기 얻어진 칼슘 함유 나노 입자에 대하여 EDX(Energy-dispersive X-ray spectroscopy) 분석을 실시하였으며, 그 결과 스펙트럼을 도 8에 나타내었다.In addition, EDX (Energy-dispersive X-ray spectroscopy) analysis was performed on the obtained calcium-containing nanoparticles, and the results are shown in FIG. 8.
실시예Example 2 2
칼슘 공급원 화합물로서 글루콘산 칼슘을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 칼슘 함유 나노 입자를 제조하였다. 그 결과 흰색의 미분말 형태의 칼슘 함유 나노 입자를 얻었으며, FE-SEM 관찰결과 실시예 1과 마찬가지로 입자 직경이 1 nm에서 900 nm 정도의 나노 입자가 얻어졌음이 확인되었다.Calcium-containing nanoparticles were prepared in the same manner as in Example 1 except that calcium gluconate was used as the calcium source compound. As a result, white fine powder-containing calcium-containing nanoparticles were obtained, and FE-SEM observation confirmed that nanoparticles having a particle diameter of about 1 nm to about 900 nm were obtained in the same manner as in Example 1.
실시예Example 3 3
다당류 화합물로서 전분을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 칼슘 함유 나노 입자를 제조하였다. 그 결과 흰색의 미분말 형태의 칼슘 함유 나노 입자를 얻었으며, FE-SEM 관찰결과 실시예 1과 마찬가지로 입자 직경이 1 nm에서 900 nm 정도의 나노 입자가 얻어졌음이 확인되었다.Calcium-containing nanoparticles were prepared in the same manner as in Example 1 except that starch was used as the polysaccharide compound. As a result, white fine powder-containing calcium-containing nanoparticles were obtained, and FE-SEM observation confirmed that nanoparticles having a particle diameter of about 1 nm to about 900 nm were obtained in the same manner as in Example 1.
실시예Example 4 4
다당류 화합물로서 카르복시메틸셀룰로오스를 사용한 것을 제외하고는 실시 예 1과 동일한 방법으로 칼슘 함유 나노 입자를 제조하였다. 그 결과 흰색의 미분말 형태의 칼슘 함유 나노 입자를 얻었으며, FE-SEM 관찰결과 실시예 1과 마찬가지로 입자 직경이 1 nm에서 900 nm 정도의 나노 입자가 얻어졌음이 확인되었다.Calcium-containing nanoparticles were prepared in the same manner as in Example 1 except that carboxymethylcellulose was used as the polysaccharide compound. As a result, white fine powder-containing calcium-containing nanoparticles were obtained, and FE-SEM observation confirmed that nanoparticles having a particle diameter of about 1 nm to about 900 nm were obtained in the same manner as in Example 1.
비교실험예Comparative Experiment 1 One
상기 실시예 1에서 얻어진 칼슘 함유 나노 입자와의 비교를 위해, 시판되는 나노 칼슘 제품에 대하여 FE-SEM을 이용하여 입자 형태를 촬영하였다. 그 결과를 도 3 내지 도 5에 나타내었다.For comparison with the calcium-containing nanoparticles obtained in Example 1, particle shapes were photographed using FE-SEM for commercially available nanocalcium products. The results are shown in FIGS. 3 to 5.
도 3은 미국 CVS pharmacy에서 판매되고 있는 굴껍질 나노칼슘 영양 보충제의 1000배 확대 FE-SEM 사진이고, 도 4는 국내에서 판매되고 있는 굴 껍질 파쇄형 나노 칼슘의 20000배 확대 FE-SEM 사진이며, 도 5는 역시 국내에 판매되고 있는 칼슘 영양 보충제의 1000배 확대 FE-SEM 사진이다. 도 3 내지 도 5를 참조하면, 기존에 시판되는 나노 칼슘제제의 경우 응집이 심하게 발생됨을 알 수 있다.3 is a 1000 times magnification FE-SEM photograph of oyster shell nanocalcium nutritional supplement sold in CVS pharmacy in the United States, FIG. 4 is a 20000 times magnification FE-SEM photograph of oyster shell fractured nano calcium sold in Korea. Figure 5 is a 1000 times magnification FE-SEM picture of calcium nutritional supplement is also sold in Korea. 3 to 5, it can be seen that in the case of conventional commercially available nano calcium preparations, aggregation occurs severely.
비교실험예
수용액 내 칼슘 나노 입자의 용해도를 알아보기 위해 상기 실시예 1에서 제조된 나노 입자와 시판되고 있는 나노칼슘(파쇄법) 각각을 상온에서 100 ml의 물에 0.2 g씩 첨가하였다.In order to determine the solubility of calcium nanoparticles in the aqueous solution, each of the nanoparticles prepared in Example 1 and commercially available nanocalcium (crushing method) were added to 0.2 ml of 100 ml of water at room temperature.
도 6은 파쇄법에 의해 제조된 나노 칼슘을 물에 용해시킨 후 상태를 보여주는 측면(a) 및 정면 사진(b)이고, 도 7은 실시예 1에서 제조된 칼슘 함유 나노 입자를 물에 용해시킨 후 상태를 보여주는 측면(a) 및 정면 사진(b)이다.6 is a side (a) and a front photograph (b) showing the state after dissolving the nano calcium prepared by the crushing method in water, Figure 7 is a calcium-containing nanoparticles prepared in Example 1 dissolved in water Side (a) and front photograph (b) which show the post state.
도 6에 따르면 파쇄법에 의해 제조된 기존의 나노 칼슘의 경우 응집도가 매 우 커 상온에서 물에 거의 용해되지 않았음을 알 수 있다. 이와 비교하여 본 발명에 따라 제조된 칼슘 함유 나노 입자의 경우, 도 7에 나타낸 바와 같이 상온에서 물에 투입시 바로 용해되어 투명한 용액을 형성하였는 바, 매우 우수한 용해특성을 보였음을 알 수 있다.According to Figure 6 it can be seen that in the case of the conventional nano calcium prepared by the shredding method, the degree of cohesion is very large and is hardly dissolved in water at room temperature. In comparison, the calcium-containing nanoparticles prepared according to the present invention, as shown in Figure 7, immediately dissolved in water at room temperature as soon as added to form a transparent solution, it can be seen that showed very excellent dissolution characteristics.
상술한 바와 같이 본 발명을 통해 화학 합성방법으로 제조된 칼슘 함유 나노 입자는 나노미터 수준으로 입자 크기를 조절할 수 있으며, 고흡수율과 고순도를 장점으로 한다. 또한 고가의 장비가 사용되지 않고 저가로 대량 생산이 가능하여 저렴한 가격으로 나노 칼슘제를 유통시킬 수 있는 효과가 기대된다.As described above, the calcium-containing nanoparticles prepared by the chemical synthesis method through the present invention can control the particle size to the nanometer level, and have advantages of high absorption rate and high purity. In addition, high-priced equipment is not used, and mass production at low cost is possible, and it is expected that the effect of distributing nano calcium agent at a low price.
도 1은 실시예 1에서 제조된 결과물의 사진이다.1 is a photograph of the result prepared in Example 1.
도 2는 실시예 1에서 제조된 칼슘 함유 나노 입자의 전계방사 주사전자현미경(FE-SEM) 사진이다. 2 is a field emission scanning electron microscope (FE-SEM) photograph of the calcium-containing nanoparticles prepared in Example 1. FIG.
도 3은 미국 CVS pharmacy에서 판매되고 있는 굴껍질 나노칼슘 영양 보충제의 1000배 확대 FE-SEM 사진이다.3 is a 1000-fold magnification FE-SEM photograph of an oyster shell nanocalcium nutritional supplement sold in the CVS pharmacy of the United States.
도 4는 국내에서 판매되고 있는 굴 껍질 파쇄형 나노 칼슘의 20000배 확대 FE-SEM 사진이다.Figure 4 is a 20000 times magnification FE-SEM picture of oyster shell crushed nano calcium sold in Korea.
도 5는 국내에 판매되고 있는 칼슘 영양 보충제의 1000배 확대 FE-SEM 사진이다.Figure 5 is a 1000 times magnification FE-SEM picture of the calcium nutritional supplement that is sold in Korea.
도 6은 파쇄법에 의해 제조된 기존 나노 칼슘 제품을 물에 용해시킨 후 상태를 보여주는 측면(a) 및 정면 사진(b)이다.Figure 6 is a side (a) and front view (b) showing the state after dissolving the existing nano-calcium product prepared by the shredding method in water.
도 7은 실시예 1에서 제조된 칼슘 함유 나노 입자를 물에 용해시킨 후 상태를 보여주는 측면(a) 및 정면 사진(b)이다.7 is a side (a) and a front photograph (b) showing a state after dissolving the calcium-containing nanoparticles prepared in Example 1 in water.
도 8은 실시예 1에서 제조된 칼슘 함유 나노 입자에 대한 EDX 분석 스펙트럼이다.8 is an EDX analysis spectrum of the calcium containing nanoparticles prepared in Example 1. FIG.
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070070373 | 2007-07-13 | ||
KR20070070373 | 2007-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20090007226A true KR20090007226A (en) | 2009-01-16 |
Family
ID=40260208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080067357A KR20090007226A (en) | 2007-07-13 | 2008-07-11 | Nano-particles containing calcium and method for preparing the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20090007226A (en) |
WO (1) | WO2009011520A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101518971B1 (en) * | 2014-02-13 | 2015-05-11 | 농업회사법인 미래에코텍 주식회사 | The Formulation of Chitosan and Ionized Calcium Complex and Its Preparing Method |
KR200481994Y1 (en) | 2016-04-04 | 2016-12-05 | 김성필 | Bar type float for sea fishing |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102471156A (en) * | 2010-05-04 | 2012-05-23 | GeoSilex金属编织有限公司 | Co2-capturing binder, production method thereof based on the selection, purification and optimisation of carbide lime, and agglomerates having an environmental activity |
KR20200002937A (en) * | 2017-04-19 | 2020-01-08 | 나노미 베.파우. | Methods and systems for making substantially monodisperse particles of material |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6342257B1 (en) * | 1996-10-28 | 2002-01-29 | Nestec S.A. | Calcium fortified foodstuff |
JP2002223736A (en) * | 2001-02-02 | 2002-08-13 | Dai Ichi Kogyo Seiyaku Co Ltd | Dispersing agent for calcium-fortified drink, and calcium- containing powder |
KR20020041789A (en) * | 2002-02-07 | 2002-06-03 | 윤동훈 | Calcium compounds for food additives |
-
2008
- 2008-07-11 WO PCT/KR2008/004080 patent/WO2009011520A2/en active Application Filing
- 2008-07-11 KR KR1020080067357A patent/KR20090007226A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101518971B1 (en) * | 2014-02-13 | 2015-05-11 | 농업회사법인 미래에코텍 주식회사 | The Formulation of Chitosan and Ionized Calcium Complex and Its Preparing Method |
KR200481994Y1 (en) | 2016-04-04 | 2016-12-05 | 김성필 | Bar type float for sea fishing |
Also Published As
Publication number | Publication date |
---|---|
WO2009011520A2 (en) | 2009-01-22 |
WO2009011520A3 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6938425B2 (en) | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and its production and usage | |
CN101340979B (en) | Method for purifying montmorillonite, purified montmorillonite and combination thereof | |
JP6049801B2 (en) | Mixed metal compound | |
KR101951857B1 (en) | Nanoparticulate phosphate adsorbent on the basis of maghemite or maghemite/magnetite, production and uses thereof | |
TWI328459B (en) | A granular material, unit dose containing the same, and the preparation process and use of the granular material | |
CN100513311C (en) | Modified smectite and method for producing the same and its application | |
JP5622579B2 (en) | Mixed metal compounds for the treatment of hyperphosphatemia | |
Ali et al. | Novel green synthesis of hydroxyapatite uniform nanorods via microwave-hydrothermal route using licorice root extract as template | |
Wang et al. | Construction of pH-responsive drug delivery platform with calcium carbonate microspheres induced by chitosan gels | |
CN102143742B (en) | Phosphate binding materials and their uses | |
CN107929313B (en) | Natural oyster calcium carbonate preparation for preventing and treating calcium deficiency and preparation method thereof | |
KR20090007226A (en) | Nano-particles containing calcium and method for preparing the same | |
JP7008624B2 (en) | Methods and Uses for Producing Carboxylate Ligand-Modified Ferric Hydroxide Colloids and Related Compositions | |
JP2020200302A (en) | Prophylactic or therapeutic agents for disorders associated with ischemic cerebrovascular disorders | |
JP6893586B2 (en) | Drugs and their manufacturing methods | |
TWI494270B (en) | Botanical added to biowaste synthetic calcium hydroxyapatite method | |
Ismail et al. | Effect of size and shape dependent of synthesized copper nanoparticle using natural honey | |
KR20090120422A (en) | Method for producing nanoparticles containing calcium by wet chemical synthesis | |
CN102258791A (en) | Cyclodextrin/Fe3O4 magnetic nano composite and medicinal inclusion compound thereof | |
TWI323176B (en) | ||
CN107257682B (en) | Medical product based on maghemite for simultaneously reducing sodium reabsorption and phosphate reabsorption in the gastrointestinal tract | |
AU2016213745B2 (en) | Granular Material Comprising Water-Insoluble Inorganic Phosphate Binders | |
JP2019151611A (en) | Composition and method for producing the same, and disease improving composition and method for producing the same | |
Cheng et al. | Colchicine-capped ZnO nanoparticles: Elucidation of their cytotoxicity potential against MDA-MB 231 cancer cells | |
CN102525938A (en) | Minocycline hydrochloride nano calcium carbonate preparation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J121 | Written withdrawal of request for trial |